ABBV vs PFE Stock Comparison

AbbVie Inc. vs Pfizer Inc.

Data as of Sep 2, 2026· market close· Healthcare· Coverage 54/66 fields· Moderate confidence
AIQ VerdictCompetitiveAIQ Comparison Conviction 6/10

PFE leads

PFE leads by 12 AIQ points, primarily on Value and Momentum, but the lead has narrowed from 18 points over 30 sessions. Wall Street currently favors ABBV on target upside.

Competitive: 4 of 6 evidence groups support PFE, its lead is narrowing, and its current signal state is conflicted.

Evidence agreement: 4 of 6Comparison trend: Weakening
ABBV

AbbVie Inc.

AIQ Score
52/100
AIQ Edge Score
5/10
PFE

Pfizer Inc.

Leads
AIQ Score
64/100
AIQ Edge Score
9/10

The Algovestiq AIQ Score currently favors PFE over ABBV, 64 versus 52 as of Sep 2, 2026. PFE's advantage is driven primarily by stronger value and momentum, while ABBV holds the stronger quality profile. PFE also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors ABBV. 4 of 6 covered evidence groups favor PFE today, and the comparison is rated Competitive on stability: the leader's advantage has been narrowing. PFE lead: Weakening — the AIQ differential moved from 18 to 12 points over 30 sessions.

Compare AbbVie Inc. and Pfizer Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.

AIQ Factor Divergence

Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.

ABBV advantage
0
PFE advantage
  • Value30%36 vs 69
    PFE +33
  • Momentum25%67 vs 78
    PFE +11
  • Risk Resilience15%44 vs 52
    PFE +8
  • Quality30%60 vs 54
    ABBV +6

4 of 6 evidence groups favor PFE. PFE’s edge is concentrated in value and momentum; ABBV keeps a meaningful quality edge.

What changed since the last close

Latest scored session 2026-09-01, compared against the prior scored session 2026-08-31.

ABBV0 AIQ

No factor moved materially.

No new signals fired.

PFE0 AIQ

No factor moved materially.

No new signals fired.

PFE's lead was unchanged in the latest snapshot.

Deeper signal detail for each name lives on its own signals page — ABBV and PFE both carry a full feed there.

The central trade-off

PFE (Pfizer Inc.): the stronger current systematic profile, led by value and momentum.

ABBV (AbbVie Inc.): the counter-case, on quality, fundamentals, analyst expectations.

The AIQ Score and Wall Street therefore point in different directions on this pair.

Which one fits your objective

The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.

Balanced

PFE

PFE on the overall AIQ Score, which weights Quality and Value at 30% each.

Growth

ABBV

ABBV on combined revenue and EPS growth.

Value

PFE

PFE on the peer-relative Value factor, by 33 points.

Momentum

PFE

PFE on the Momentum factor, by 11 points.

Lower downside

PFE

PFE on Risk Resilience, by 8 points.

Analyst upside

ABBV

ABBV on implied upside to the consensus price target.

AIQ vs Wall Street

The model and the Street disagree here: AIQ favors PFE, analyst targets favor ABBV. That disagreement is the most useful thing on this page.

MeasureABBVPFENote
Implied upside to target+8.2%-2.3%ABBV has more room
Target dispersion+24.3%+17.7%Lower is tighter analyst agreement
ConsensusBuyHoldContext, not a primary driver
Analysts covering136Higher coverage generally improves confidence

The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.

Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.

AIQ Agreement Matrix

4 of 6 covered evidence groups favor PFE. A wide gap backed by one group is a weaker case than a narrow gap backed by five.

Evidence groupFavorsReading
AIQ ScorePFE52 vs 64
FundamentalsABBVon balancerevenue growth 13.3% vs 4%; EPS growth 4.2% vs -109.2%; ROE -136.6% vs 4.9%; gross margin 74.1% vs 71.3%; operating margin 29.8% vs 25.1% — ABBV takes 4 of 5 decided legs, not all of them
ValuationPFEValue 36 vs 69
TechnicalsPFEPrice vs 50-day 2.3% vs 12.5%; vs 200-day 12.6% vs 9%
Risk ResiliencePFERisk Resilience 44 vs 52
Analyst expectationsABBVTarget upside 8.2% vs -2.3%

✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ABBV and PFE and are excluded from the count.

AIQ Decision Stability

Competitive

The two are close enough that your objective, not the score, should decide.

  • The AIQ gap is wide at 12 points. (supports the conclusion holding)
  • The leader's advantage has been narrowing. (argues the conclusion is provisional)
  • The leader is throwing conflicting signals. (argues the conclusion is provisional)

Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on PFE.

How the comparison changed

120 daily snapshots · Apr 20 Sep 1

PFE lead: Weakening — the AIQ differential moved from 18 to 12 points over 30 sessions.

Apr 20ABBV leads above the line · PFE leads belowSep 1
Today
PFE +12
52 vs 64
7 sessions ago
PFE +9
54 vs 63
30 sessions ago
PFE +18
47 vs 65
90 sessions ago
ABBV +5
56 vs 51

The lead changed hands 5 times in this window, most recently on Jul 13 when PFE moved ahead of ABBV.

AIQ Signal Divergence

Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.

ABBVConflicted

3 bullish / 1 bearish, conflicted

  • Golden Cross Active bullish, trend, long horizon (10.87%)
  • EMA Ribbon Expansion Bullish bullish, trend, medium horizon
  • Uptrend Structure Active bullish, trend, long horizon
PFEConflicted

4 bullish / 1 bearish / 1 neutral, conflicted

  • Death Cross Active bearish, trend, long horizon (1.81%)
  • Bollinger Band Squeeze neutral, volatility, short horizon
  • Keltner Channel Breakout bullish, volatility, short horizon

PFE leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.

Price vs model alignment

Whether the latest session's price move confirms what the model did over the same session, or contradicts it.

ABBVNo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.66%, AIQ 0 points).

PFENo material change

Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.02%, AIQ 0 points).

What would flip this result

A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.

  1. 1ABBV closes the Value gap — currently 33 points behind, the largest single contributor to PFE's edge.
  2. 2ABBV generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover.
  3. 3PFE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once.
  4. 4The narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 12-point move would eliminate PFE's advantage entirely.

The full evidence

Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.

Fundamentals

ABBV leads on balance
MetricABBVPFE
Revenue growth (YoY)13.3%4%
EPS growth (YoY)4.2%-109.2%
Gross margin74.1%71.3%
Operating margin29.8%25.1%
Return on equity-136.6%4.9%
Debt to equity-11.930.74

Technicals

PFE has the stronger structure
MetricABBVPFE
RSI (14)57.669.2
ADX (14)23.544
Price vs 50-day2.3%12.5%
Price vs 200-day12.6%9%
Volatility (1M, annualized)21.1%23.1%

Risk

PFE is the more resilient
MetricABBVPFE
Beta-0.090.3
Sharpe ratio0.780.57
Sortino ratio1.290.99
Max drawdown-19.2%-17.1%
Current drawdown-3.6%-0.4%
Annualized volatility26.6%23.9%
Value at risk (95%)-2.4%-2.2%

Straight answers

Each answer is regenerated from the current snapshot, not written once and left to age.

Which is better, ABBV or PFE?

On the Algovestiq AIQ Score, PFE is the stronger of the two as of Sep 2, 2026, scoring 64 against ABBV's 52. The edge comes from value and momentum. ABBV is not without a case — it holds the better quality profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.

Is ABBV or PFE the better buy right now?

PFE carries the stronger systematic profile as of Sep 2, 2026, and the comparison is rated Competitive — 4 of 6 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.

Why does the AIQ Score favor PFE over ABBV?

The composite weights Quality at 30%, Value at 30%, Momentum at 25% and Risk Resilience at 15%. PFE leads Value by 33 points; PFE leads Momentum by 11 points; PFE leads Risk Resilience by 8 points. Where the two split, the factor with the larger weight carries the result.

Which has more analyst upside, ABBV or PFE?

Analyst price targets imply +8.2% upside for ABBV and -2.3% for PFE, so the Street currently favors ABBV. That points the opposite way to the AIQ Score, which favors PFE. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.

Which is better value, ABBV or PFE?

PFE is the better-valued of the two on the peer-relative Value factor. PFE on the peer-relative Value factor, by 33 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.

Which has stronger growth, ABBV or PFE?

ABBV on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.

Which has stronger momentum, ABBV or PFE?

PFE on the Momentum factor, by 11 points. Momentum carries 25% of the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.

Which is riskier, ABBV or PFE?

PFE is the more resilient of the two, so the other name carries the higher downside risk. PFE on Risk Resilience, by 8 points. The Risk Resilience factor weights 15% of the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.

Is ABBV more profitable than PFE?

The profitability evidence is mixed: gross margin 74.1% vs 71.3%; operating margin 29.8% vs 25.1%; roe -136.6% vs 4.9%. ABBV leads on two measures and PFE on one measure, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.

Is PFE's lead over ABBV getting stronger or weaker?

PFE lead: Weakening — the AIQ differential moved from 18 to 12 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-04-20 and 2026-09-01. The lead has changed hands 5 times in that window, most recently on 2026-07-13, when PFE moved ahead of ABBV.

What would change the ABBV vs PFE verdict?

The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: ABBV closes the Value gap — currently 33 points behind, the largest single contributor to PFE's edge; ABBV generates a confirmed bullish trend signal it does not currently carry, such as MACD Bullish Crossover; PFE's conflicting signal state resolves bearish — it currently carries 4 bullish and 1 bearish rules at once; the narrowing continues — the lead has already given back 6 points over 30 sessions, and a further 12-point move would eliminate PFE's advantage entirely.

What do the current signals say about ABBV and PFE?

ABBV: 3 bullish / 1 bearish, conflicted. PFE: 4 bullish / 1 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ABBV is Golden Cross Active (bullish, long horizon). On PFE it is Death Cross Active (bearish, long horizon).

Compare ABBV and PFE with others

How this comparison is scored

The Algovestiq AIQ Score composites four factors — Quality (30%), Value (30%), Momentum (25%) and Risk (15%). Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.

The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.

How to use side-by-side comparison →

This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.